Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): From bench to bedside

Abdel‐Rahman, Omar

doi:10.1016/j.critrevonc.2014.11.009

Cited by 12 publications

(6 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumour‐stromal interactions are also important for thyroid cancer progression, and in particular tumour expression of vascular endothelial growth factor (VEGF) and platelet‐derived growth factor (PDGF) and their interactions with cognate receptors on stromal fibroblasts appear also to be key processes mediating local progression (Figure ) . Angiogenesis is a hallmark of many cancers, including DTC . VEGF is upregulated in DTC and one of its coreceptors, NRP‐2, has been implicated in metastases through enhancement of invasion and motility in thyroid cancer cells .…”

Section: Biological Mechanisms For Radioiodine Refractory Diseasementioning

confidence: 99%

See 1 more Smart Citation

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Gild

Topliss

Learoyd

et al. 2017

Clinical Endocrinology

View full text Add to dashboard Cite

Prognosis from differentiated thyroid cancer is worse when the disease becomes refractory to radioiodine. Until recently, treatment options have been limited to local therapies such as surgery and radiotherapy, but the recent availability of systemic therapies now provides some potential for disease control. Multitargeted kinase inhibitors (TKIs) including lenvatinib and sorafenib have been shown to improve progression-free survival in phase III clinical trials, but are also associated with a spectrum of adverse effects. Other TKIs have been utilized as "redifferentiation" agents, increasing sodium iodide symporter expression in metastases and thus restoring radioiodine avidity. Some patients whose disease progresses on initial TKI therapy will still respond to a different TKI and clinical trials currently in progress will clarify the best options for such patients. As these drugs are not inexpensive, care needs to be taken to minimize not only biological but also financial toxicity. In this review, we examine the basic biology of radioiodine refractory disease and discuss optimal treatment approaches, with specific focus on choice and timing of TKI treatment. This clinical field remains fluid, and directions for future research include exploring biomarkers and considering adjuvant TKI use in certain patient groups.

show abstract

Section: Biological Mechanisms For Radioiodine Refractory Diseasementioning

confidence: 99%

“…16 Angiogenesis is a hallmark of many cancers, including DTC. 17 VEGF is upregulated in DTC and one of its coreceptors, NRP-2, has been implicated in metastases through enhancement of invasion and motility in thyroid cancer cells. 18,19 Several studies have shown a correlation between VEGF receptor expression and metastasis in PTC.…”

Section: Introductionmentioning

confidence: 99%

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Gild

Topliss

Learoyd

et al. 2017

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…VEGF inhibitors have been used to block the angiogenesis and to induce apoptosis in thyroid cancer (Peng et al, 2015). Both VEGF and VEGFR have been observed to have prominent prognostic association in differentiated thyroid cancer (Zhou et al, 2012;Abdel-Rahman, 2015). Tyrosine kinase inhibitors which targeted on VEGF and VEGFR have been used in the therapeutic management of differentiated thyroid carcinoma (Fallahi et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study

Razy

Rahman

Win

2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Introduction: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays an important role in thyroid cancer. VEGF is known to have high affinity to VEGF receptors such as VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and studies showed the increasing incidence of PTC arising in nodular hyperplasia. Targeted therapy on these growth factors and receptors are used in management of both differentiated and undifferentiated thyroid carcinoma. This study aims to determine the expression of VEGF and VEGF receptors (VEGFR) in thyroid nodular hyperplasia and PTC. Methods: A cross-sectional study based on paraffinized archival tissue blocks of 113 nodular hyperplasias and 67 PTC from the thyroidectomy specimens in the year of 2003 to 2014. The tissue sections were then stained by immunohistochemistry for VEGF, VEGFR-1 and VEGFR-2. The lymph node involvement and extrathyroid extension also were determined. Results: The mean age of PTC patients was 44.7±15.8 years and nodular hyperplasia were 42.2±13.6 years. There was a statistical difference of VEGFR-1 (p=0.028) and VEGFR-2 (p=0.003) expression between nodular hyperplasia and PTC. However, no significant difference of VEGF expression (p=0.576) between both diseases. Co-expression of VEGF and VEGFR-1 was significant in both nodular hyperplasia (p=0.016) and PTC (p=0.03), meanwhile no relevant relationship for VEGF and VEGFR-2 expression (p>0.05). No significant association (p>0.05) between lymph node status and extrathyroid extension with age groups, gender, VEGF and VEGFR expression. Conclusions: VEGF, VEGFR-1 and VEGFR-2 showed overexpression in both nodular hyperplasia and PTC. The expression of VEGFR-1 and VEGFR-2 are more significant in PTC with relevant co-expression of VEGF and VEGFR-1. Therefore, the inhibition of VEGFR offers a promising prospect for tumour management in thyroid carcinoma.

show abstract

“…Pathologically, aberrant angiogenic mechanisms play a major role in cancer growth and are a necessary process for tumor metastasis [21,22] . Binding of VEGF to its receptors (VEGFR-1, VEGFR-2) initiates an angiogenic signaling process with subsequent increased vascular permeability and endothelial cell proliferation [23].…”

Section: Discussionmentioning

confidence: 99%

Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis

Abdel‐Rahman

Elhalawani²

2014

Chemotherapy

Self Cite

View full text Add to dashboard Cite

Background: We performed a systematic review and meta-analysis of the risk of proteinuria associated with ramucirumab. Methods: Eligible studies included randomized phase II and III trials of patients with solid tumors on ramucirumab, describing events of all-grade and high-grade proteinuria. Results: Our search strategy yielded 170 potentially relevant citations from PubMed/Medline, CENTRAL Cochrane database, ASCO and ESMO meeting libraries. After exclusion of ineligible studies, a total of 11 clinical trials were considered eligible for the meta-analysis. The relative risk (RR) of all-grade proteinuria was 3.31 (95% CI 2.48-4.42; p < 0.00001). Moreover, the RR of high-grade proteinuria was 5.28 (95% CI 2.32-12.01; p < 0.0001). Conclusions: Our meta-analysis has demonstrated that ramucirumab use is associated with an increased risk of all-grade and high-grade proteinuria. Early detection strategies should be employed in those patients to prevent the progression to more sinister renal disease.

show abstract

Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): From bench to bedside

Cited by 12 publications

References 58 publications

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study

Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About